MK-4827 (Niraparib)

Catalog No. A11026

MK-4827 (Niraparib)是一种新型有效的口服生物可利用的PARP-1和PARP-2抑制剂。
  • Joseph M Gozgit, .et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer cell, 2021, Jul 22;S1535-6108(21)00340-8 PMID: 34375612
  • Ann-Katrin Hopp, .et al. Mitochondrial NAD+ Controls Nuclear ARTD1-Induced ADP-Ribosylation, Molecular cell, 2021, Jan 21; 81(2): 340?C354 PMID: 33450210
  • Bian C, .et al. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression, Nat Commun, 2019, Feb 11;10(1):693 PMID: 30741937
  • Tahira Baloch, .et al. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1, BMC Cancer, 2019, Jan 10;19(1):44 PMID: 30630446
  • Khalid Hilmi, .et al. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair, Sci Adv, 2017, May; 3(5): e1601898 PMID: 28560323
Catalog Num A11026
M. Wt 320.4
Formula C19H20N4O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1038915-60-4
Synonyms MK4827
SMILES C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
MK-4827 (Niraparib)是一种新型有效的口服生物可利用的PARP-1和PARP-2抑制剂。
In vitro (25°C) DMSO 60 mg/mL (187.27 mM)
Water Insoluble
Ethanol 60 mg/mL (187.27 mM)
In vivo 10% DMSO+40% PEG 300+5% Tween 80+ddH2O 9 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 31.21 mL 156.05 mL 312.11 mL
0.5 mM 6.24 mL 31.21 mL 62.42 mL
1 mM 3.12 mL 15.61 mL 31.21 mL
5 mM 0.62 mL 3.12 mL 6.24 mL

*The above data is based on the productmolecular weight 320.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.